Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 5-Jun 4:05 PM ET)
Where short sellers are betting in micro- and small-cap stocks
Seeking Alpha News (Thu, 4-Jun 9:45 AM ET)
Globe Newswire (Mon, 1-Jun 7:30 AM ET)
Intellia’s Lonvo-z Cuts HAE Attacks by 87% in Phase 3; Cash Extends Runway Through 2028
Market Chameleon (Mon, 11-May 3:53 AM ET)
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Globe Newswire (Mon, 11-May 7:30 AM ET)
Intellia Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 5-May 7:30 AM ET)
NTLA Announces $180 Million Public Offering: What This Means for the Company’s Future
Market Chameleon (Wed, 29-Apr 3:36 AM ET)
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
Globe Newswire (Wed, 29-Apr 7:00 AM ET)
Intellia Announces Proposed Public Offering of Common Stock
Globe Newswire (Mon, 27-Apr 4:01 PM ET)
Market Chameleon (Mon, 27-Apr 3:05 AM ET)
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Intellia Therapeutics trades on the NASDAQ stock market under the symbol NTLA.
As of June 9, 2026, NTLA stock price declined to $12.89 with 5,416,839 million shares trading.
NTLA has a beta of 1.76, meaning it tends to be more sensitive to market movements. NTLA has a correlation of 0.04 to the broad based SPY ETF.
NTLA has a market cap of $1.80 billion. This is considered a Small Cap stock.
Last quarter Intellia Therapeutics reported $15 million in Revenue and -$.81 earnings per share. This beat revenue expectation by $896,968 and exceeded earnings estimates by $.09.
In the last 3 years, NTLA traded as high as $47.48 and as low as $5.90.
The top ETF exchange traded funds that NTLA belongs to (by Net Assets): ARKK, VTI, XBI, VB, ARKG.
NTLA has outperformed the market in the last year with a price return of +59.3% while the SPY ETF gained +24.3%. However, in the short term, NTLA had mixed performance relative to the market. It has underperformed in the last 3 months, returning -4.1% vs +9.9% return in SPY. But in the last 2 weeks, NTLA shares have fared better than the market returning +2.3% compared to SPY -1.2%.
NTLA support price is $12.79 and resistance is $14.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NTLA shares will trade within this expected range on the day.